IP Library Patent Application 15733853
Patent Application
App. No. 15/733,853

Gene Targeting

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/733,853
Abstract

Methods, reagents and compositions for providing more accurate and reliable genetic modification are provided. In particular, a nucleic acid encoding a fusion protein comprising a 5′ to 3′ DNA exonuclease domain and an RNA binding domain is described. Also provided are methods, reagents and compositions for in vivo genetic modification of the genome of a human or animal cell. Furthermore, the present application relates to uses of the said methods, reagents and compositions in the treatment of disease and production of transgenic animals.

Claims (28)

1 . A nucleic acid encoding a first fusion protein comprising a 5′ to 3′ DNA exonuclease domain and an RNA binding domain.

2 . A nucleic acid according to claim 1 , wherein the exonuclease is λ-exo.

3 . A nucleic acid according to claim 1 , for inhibition of NHEJ during transformation of a cellular genome so as to promote HDR.

4 . A nucleic acid according to any of claim 1 , for transformation of a eukaryotic cell in concert with an RNA-guided endonuclease.

5 . A nucleic acid composition comprising a nucleic acid according to claim 1 and a nucleic acid encoding a second fusion protein comprising an endonuclease domain and a binding domain for an origin of replication.

6 . A nucleic acid composition comprising a nucleic acid according to claim 1 and a nucleic acid encoding a third fusion protein comprising a recombination inducing domain and an RNA binding domain.

7 . A nucleic acid composition comprising a nucleic acid according to claim 1 and a nucleic acid encoding a fourth fusion protein comprising a domain comprising an inhibitor of the mismatch repair pathway; and an RNA binding domain.

8 . A nucleic acid composition comprising a nucleic acid according to claim 1 and a nucleic acid encoding a fifth fusion protein comprising a Holliday junction resolvase domain and an RNA binding domain.

9 . A nucleic acid according to claim 1 , wherein the RNA binding domain binds to the RNA component of an RNA guided endonuclease for use in transformation mediated by the RNA-guided endonuclease.

10 . A method of transforming the genome of a human or animal cell comprising the steps of:

a. expressing an RNA-guided endonuclease in the cell or introducing the RNA-guided endonuclease into the cell;

b. expressing in the cell or introducing into the cell a sequence specific guide RNA to direct cleavage by the endonuclease domain to a specific locus

c. expressing in the cell the nucleic acid of claim 1 or introducing into the cell the first fusion protein of claim 1 .

11 . A method according to claim 10 , wherein the exonuclease is a dsDNA exonuclease.

12 . A method according to claim 10 for modifying a genome, wherein a double strand break is introduced into the genome in the presence of an exogenous donor nucleic acid sequence comprising a donor nucleic acid sequence as a template for modifying the chromosome or as an exogenous sequence to be integrated into the chromosome, and a DNA repair mechanism modifies the genome via homology-directed repair (HDR), the method comprising:

suppressing non-homologous end joining (NHEJ) repair of the break to promote repair by HDR by expressing in the cell the nucleic acid of claim 1 or introducing into the cell the first fusion protein of claim 1 .

13 . A method according to claim 1013 , 11 or 12 , further comprising the steps of:

a. expressing in the cell the nucleic acid of claim 1 ; or

b. introducing into the cell the fusion protein of claim 1 .

14 . A method according to claim 13 , comprising expressing in the cell a nucleic acid of claim 1 or introducing into the cell a fusion protein of claim 1 , wherein the RNA binding protein domains of the respective fusion proteins bind to different RNA sequences.

15 . (canceled)

16 . Use a nucleic acid according to claim 1 in transformation of a human or animal cell using an RNA-guided endonuclease.

17 - 24 . (canceled)

25 . A nucleic acid according to claim 6 , wherein the RNA binding domain binds to the RNA component of an RNA guided endonuclease for use in transformation mediated by the RNA-guided endonuclease.

26 . A nucleic acid according to claim 7 , wherein the RNA binding domain binds to the RNA component of an RNA guided endonuclease for use in transformation mediated by the RNA-guided endonuclease.

27 . A nucleic acid according to claim 8 , wherein the RNA binding domain binds to the RNA component of an RNA guided endonuclease for use in transformation mediated by the RNA-guided endonuclease.

28 . A method according to claim 13 , wherein the binding domain for an origin of replication of the second fusion protein binds to the origin of replication of the donor nucleic acid.

29 . Use a nucleic acid according to claim 5 in transformation of a human or animal cell using an RNA-guided endonuclease.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2025
From: ALGENTECH
To: ALGENSCRIBE
Reel/Frame 071946/0756 →
LICENSE Recorded Apr 21, 2023
From: ALGENTECH
To: ALGENSCRIBE
Reel/Frame 063440/0492 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2021
From: SOROKIN, ALEXANDER; MALCUIT, ISABELLE; VLAD, FLORINA
To: ALGENTECH SAS
Reel/Frame 058306/0558 →